Selected Reports From
The 5th International Congress on
Drug Therapy in HIV Infection,
Glasgow, Scotland:   

 Recent Reports  

• When To Begin Therapy: Glasgow & Contrasting Retrovirus Data Presentations
  Fifth International Congress on Drug Therapy in HIV Infection - October 22-26, 2000 , Glasgow, Scotland, UK
       Written for NATAP by W. David Hardy, M.D.
  Retrovirus & Glasgow studies: Initial Response To Therapy Based on CD4 & Viral Load Likelihood of Virologic Failure (500 copies/ml)
       Written by Jules Levin
   (01/05/2001)
  
  

• UPDATE on the 3 Nevirapine Studies Reporting on Liver Enzyme Elevations & Clinical Hepatitis from Glasgow AIDS Conference
    

• 3 Nevirapine Studies Reporting on Liver Enzyme Elevations & Clinical Hepatitis

  Live Reports from Glasgow, Scotland  

Written by Jules Levin, October 2000 

• Report 15 -Effect of pregnancy on chronic hepatitis C: a case-control study
  
  

• Report 14  - Does Stopping PI Reverse Lipodystrophy?
  
  

• Report 13  - Should lactate levels be measured?
  Chronic liver failure and persistent mitochondrial dysfunction 2 years after nucleoside reverse transcriptase inhibitor (NRTI)-induced acute hepatitis and lactic acidemia (abstract P165A).
  
  

• Report 12  - Cytokine Dysregulation & Lipodystrophy
  
  

• Report 11  - Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
  
  

• Report 10  - HIV Therapy Strategies: Initial, Second Line and Salvage
       Reported for NATAP by Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK
  
  

•  Report 9  - Prevention of Nevirapine-associated Rash Using Slow Dose Escalation, Antihistaminics or Corticosteroids
  
  

• Report 8  - Identifying D4T Resistance
  
  

•  Report 7  - New Phenotype Resistance Testing Standards from Virco
  
  

•  Report 6  - ABT-378 (Kaletra) in Multiple PI Experienced: 48 Week Update
  
  

•  Report 5  - Glasgow Wednesday Brief Update Report
                     ABT-378 & Resistance
                    Bone Problems in HIV
                    Neviripine & Hepatitis
                    Immune Function & When to Begin Therapy
                    IL-2

•  Report 4  - The Risk of Resistance From Treatment Interruptions
  
  

•  Report 3  - ABT-378 vs Nelfinavir (+d4T/3TC)
  
  

•  Report 2  - Swiss-Spanish Strategic Interruption Study in Chronic Infection in Group Well Controlled Virologically
  
  

•  Report 1 - Once A Day Regimen: Efavirenz + DDI and 3TC or FTC